We are a clinical-stage biotechnology company focused on restoring function by developing therapeutics that activate a person’s innate regenerative potential.
Frequency is leading a new category in regenerative medicine designed to activate a person’s innate regenerative potential, within the body, to repair tissue and restore function.
Developing small-molecule treatments to reverse the debilitating impact of degenerative diseases
Hearing loss caused by damage to the sensory cells of the ear impacts hundreds of millions of people globally. Currently there are no FDA-approved treatments to address the underlying condition.
Neurologist and Epidemiologist, NYU School of Medicine
Professor of Neuroimmunology, University of Cambridge
Professor of Neurology and Ophthalmology, NYU Grossman School of Medicine
Independent Consultant. Former Chief Clinical Research Officer and Vice Chairman for Research and Development in the Neurological Institute, Cleveland Clinic